SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors

Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.

Trial Details

NCT ID
NCT06562647
Phase
NA
Sponsor
Cell Origin Biotech (Hangzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • SY001
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Linyi, China|35.06306,118.34278

Key Eligibility Criteria

  • Patients with pathologically diagnosed advanced ovarian cancer/pancreatic cancer who have failed at least 1 prior lines treatment, and tumor tissue…
  • According to the RECIST 1.1, there is measurable tumor lesions (non-lymph node lesion 10mm in length or lymph node lesion 15mm in diameter measured…
  • Eastern Cooperative Oncology Group (ECOG) score of 2 and satisfactory major organ functions;
  • Estimated life expectancy \>3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →